The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...